CD86
Overview
CD86 (also known as B7-2) is a co-stimulatory ligand expressed on antigen-presenting cells and activated immune cells. Like CD80, CD86 binds CD28 to provide T-cell co-stimulation and binds CTLA-4 to deliver inhibitory signals. CD86 is typically expressed earlier and at higher levels than CD80 during immune activation. Under PD-1 blockade, CD86 is induced as part of the pharmacological on-therapy immune program.
Alterations observed in the corpus
- CD86 was identified as a component of the TCR/co-stimulatory immunological synapse upregulated on-therapy in melanoma patients receiving nivolumab (anti-PD-1). CD86 was specifically listed among the TCR/co-stimulatory axis genes enriched in the contraction-phenotype DEG set (695 genes, q < 0.10) and the broader pharmacologic on-therapy response. PMID:29033130
Cancer types (linked)
- SKCM: CD86 on-therapy upregulation was observed in melanoma patients on nivolumab, as part of a coordinated TCR/co-stimulatory gene program enriched in the genomic-contraction phenotype that predicted superior clinical outcomes in independent immunotherapy cohorts. PMID:29033130
Co-occurrence and mutual exclusivity
Therapeutic relevance
- The on-therapy induction of CD86 and the broader co-stimulatory gene program under nivolumab supports the mechanistic model that anti-PD-1 therapy reactivates T-cell co-stimulation in the tumor microenvironment, relevant to the rationale for combining PD-1 and CTLA-4 blockade. PMID:29033130
Open questions
- Whether differential CD86 vs CD80 on-therapy induction distinguishes responder subsets was not reported in this study. PMID:29033130
Sources
This page was processed by crosslinker on 2026-05-15.